VioQuest and Greenwich Sign Letter of Intent to Merge

VioQuest Pharmaceuticals signed a non-binding letter of intent to complete a merger transaction with Greenwich Therapeutics, a privately held New York biotechnology company focused on the development of novel compounds with broad therapeutic applications in oncology. In the proposed merger, VioQuest would acquire two anticancer agents -- Sodium Stibogluconate (SSG) and API-2. As a result of the proposed merger, the stockholders of Greenwich Therapeutics will receive up to approximately 47 percent of VioQuest Pharmaceuticals on a fully diluted, post-merger basis.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050503006377&newsLang=en)